Ipv-Boostrix (Aluminium Phosphate, Diphtheria Toxoid Adsorbed On Aluminium Hydroxide, Hydrated And Aluminium Phosp)

Ipv-Boostrix is a diphtheria vaccine used to stimulate protective immunity against Corynebacterium diphtheriae.

• Diphtheria: induces active immunity to prevent diphtheria infection in children and adults.
• Booster immunization: restores protective antibody levels in individuals previously vaccinated.
• Travel vaccination: recommended for travelers to regions where diphtheria remains endemic.

• Ipv-Boostrix contains diphtheria toxoid chemically linked to aluminium phosphate adjuvant. After intramuscular injection, the toxoid is taken up by antigen‑presenting cells, while aluminium salts enhance the immune response by promoting depot formation and stimulating innate pathways. This results in the production of diphtheria‑specific antibodies and memory cells that confer long‑lasting protection.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the site of administration.
• Redness or swelling: localized erythema that resolves within a few days.
• Low‑grade fever: transient temperature rise often accompanied by mild fatigue.
• Headache: occasional mild headache following vaccination.
• Fatigue: short‑term tiredness reported by some recipients.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Guillain‑Barré syndrome: rare neurological disorder that may develop after vaccination.
• Seizures: uncommon occurrence, particularly in individuals with a history of febrile seizures.
• Prolonged high fever: fever persisting beyond 48 hours and exceeding 40 °C.
• Hypotension: sudden drop in blood pressure, potentially leading to dizziness or fainting.

Ipv-Boostrix should be administered only after evaluating the individual's medical history and current health status.

• Allergy screening: avoid use in persons with known hypersensitivity to diphtheria toxoid or aluminium compounds.
• Acute illness: defer vaccination in individuals with moderate or severe febrile illness.
• Observation period: monitor the recipient for at least 15 minutes post‑injection for immediate reactions.
• Immunocompromised patients: vaccine may elicit a reduced immune response; consult a healthcare professional.
• Pregnancy and lactation: discuss potential benefits and risks with a qualified provider before administration.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines can interact with other agents that modify immune function or mask adverse reactions.

Major Interactions (Avoid)

• Live attenuated vaccines: avoid co‑administration within 4 weeks as it may reduce efficacy of either product.
• Immunoglobulin therapy: may neutralize the vaccine antigen and diminish the immune response.

Moderate Interactions (Monitor Closely)

• Immunosuppressive drugs: may lower antibody production, requiring serologic monitoring.
• Antipyretics (e.g., acetaminophen): can mask post‑vaccination fever, making it harder to assess reaction severity.
• Blood products: transfusions shortly before or after vaccination may interfere with antigen presentation.